Skip to Content

Polatuzumab vedotin with R-CHP for patients with diffuse large B-Cell lymphoma

Adding polatuzumab vedotin, an antibody drug, to a treatment regimen together with rituximab, cyclophosphamide, doxorubicin, and prednisone (pola-R-CHP) significantly affects progression-free survival in patients with previously untreated diffuse large B-Cell lymphoma.

Get access

If you are a doctor or other health professional, you can access the entire article by creating a profile on BestPractice Nordic.

Back to top